Alkermes, a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology, completed the spin-off its oncology business into an independent, publicly-traded company. "The separation of our oncology business was an important element of our strategy to transform Alkermes into a pure-play neuroscience company with the potential to generate strong profitability and cash flow. With a topline driven by the growth of our proprietary commercial products, proven drug development capabilities, and an important pipeline opportunity in our ALKS 2680 orexin program, we believe we are well positioned to drive value for Alkermes shareholders," Richard Pops, Alkermes Chief Executive Officer.